Early prostate specific antigen decline and its velocity are independent predictive factors for outcomes of mCRPC patients treated with abiraterone acetate

• Jiang-Yi Wang,
• Guo-Peng Yu,
• Long Li,
• Guo-Wen Lin,
• Ding-Wei Ye

Affiliations

Jiang-Yi Wang

Department of Urology, Fudan University Shanghai Cancer Center

Guo-Peng Yu

Department of Urology, Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine

Long Li

Department of Urology, Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine

Guo-Wen Lin

Department of Urology, Fudan University Shanghai Cancer Center

Ding-Wei Ye

Department of Urology, Fudan University Shanghai Cancer Center